CN101401817A - Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone - Google Patents
Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone Download PDFInfo
- Publication number
- CN101401817A CN101401817A CNA2008100465018A CN200810046501A CN101401817A CN 101401817 A CN101401817 A CN 101401817A CN A2008100465018 A CNA2008100465018 A CN A2008100465018A CN 200810046501 A CN200810046501 A CN 200810046501A CN 101401817 A CN101401817 A CN 101401817A
- Authority
- CN
- China
- Prior art keywords
- stone
- taken
- capsules
- urinary
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a method for preparing a chemical drug dissolving a urinary stone. The urinary system stone in human body comprises a kidney stone, a ureter stone, a vesical stone and a urethral stone. The main means of treating the urinary stone adopt a crusher and an operation, but the means can not meet social needs because of a plurality of contraindications and high after-operation recurrence rate, so that in the society, a medical drug dissolving the stone is urgently needed. However, so far, no drug dissolving the stone has been found and used. The preparation method comprises the following: the invention is a compound; and potassium nitrate and aluminum potassium sulfate containing crystal water are mixed according to the weight ratio of 1 to 1, ground, encapsulated and is taken by a patient. The taking method is as follows: under general conditions, 6 to 10 capsules with about between 5 and 10 grams are taken for each day; for a patient with severe hydronephrosis, about 15 capsules are taken for each day; when the hydronephrosis is discharged, the dose is reduced; the capsules are taken after dinner, and taken for multiple times as possible, and 2 to 3 capsules for each time properly; moreover, the patient needs to drink more water; after curing, for preventing the urinary stone, one capsule is taken for each day, so that people in high occurrence areas and ages can take the capsules for early prevention.
Description
Technical field
The present invention provides a kind of preparation method of dissolving the urinary calculi chemical drugs, and the human body urinary system calculus has comprised renal calculus, ureteral calculus, vesical calculus, calculus of urethra.
The means of treatment urinary calculi mainly are lithotrite and operation at present.Many and the high reason of postoperative recurrence rate can not satisfy social needs above means owing to contraindication.Society presses for a kind of internal medicine medicine that can dissolve calculus.But the medicine that the dissolving calculus is not arranged so far yet is found and uses.
Summary of the invention
Preparation method: the present invention is a kind of chemical compound, be by potassium nitrate with contain the water of crystallization aluminum potassium sulfate and mix the back porphyrize at 1: 1, take after pouring into capsule.
Background technology
Find thinking: in 32 kinds of compositions of known urinary calculi, oxalates, phosphate, urine are arranged Hydrochlorate, Cystine etc. only do not have the nitric acid composition, illustrate that urinary calculus is to repel nitrate, can The medicine of nitrate as the treatment calculus.
Invention thinking: (have the people of gastritis can if consider that potassium nitrate is can not be in stomach after oral entirely molten This situation can appear), entering behind the enteron aisle will be under salmonella or colibacillary effect, Resolve into nitrite and draw poisoning. Because the known crystallization water aluminum potassium sulfate that contains can make bacterioprotein solidifying Gu, so with potassium nitrate with contain that crystallization water aluminum potassium sulfate is mixed to contain use, can prevent nitrite poisoning Generation. Through a large amount of clinical practice, find that these two kinds of chemical substances use together than independent use The curative effect of potassium nitrate is much higher.
Potassium nitrate is made behind the powder almost molten entirely at gastric, in blood, because K
+, Na
+Osmosis, can combine with in-house moisture content, carry a large amount of moisture content by glomerule to kidney, do not absorbed, so be diuresis by renal tubules.Nitrate anion is very active, can combine with the calcium in the calculus, makes calculus surfaces loosening.The oxidability of nitric acid is strong, and except that gold and platinum, can generate nitrate, concentrated hydrochloric acid and concentrated nitric acid volume ratio with most of metal is that 3: 1 mixture is called chloroazotic acid, and gold and platinum also are dissolved in chloroazotic acid (gastric has hydrochloric acid, and PH is about 1.9).
Potassium nitrate molecular formula: KNO
3, molecular weight: 101, fusing point: 334 ℃; Density: (relative density water=1) 2.11; Appearance character: water white transparency is side or three crystallographic system granule or white powders tiltedly; Boiling point: 400 ℃ of decomposition; Dissolubility: soluble in water, be insoluble to ethanol, ether; Good stability.Main uses: make cigarette, match, gunpowder, medicine, glass.
Health hazard: 1, suck, for respiratory tract zest is arranged through skin absorption or suction this product dust, can cause pulmonary edema, a large amount of suctions can cause that the blood red amount of high ferro is white, dizziness, headache, cyanosis occur, feel sick, vomit.2, oral, orally too much can cause tormina, hemafecia.
Toxicological information: 1, acute toxicity, LD50; 3750mg/kg (rat footpath mouth).2, zest; Rabbit is through eye 100mg (24 hours) moderate, and rabbit percutaneous 500mg (24 hours) is slight.
Hazard property: strong oxidizer, to meet when combustible catches fire and can encourage the intensity of a fire, danger can set off an explosion when contacting with Organic substance Reducing agent combustibles such as sulfur, phosphorus etc.During combustion decomposition, emit deleterious nitrogen oxide.
The medicine relevant with nitric acid or potassium nitrate: 1, the nitroglycerine of taking as explosive raw material can suppress anginal outbreak, and reason is that decomposition forms nitric oxide and makes coronary artery expansion.After the middle aged patient that the inventor merged coronary heart disease once for a routine urinary stone takes medicine of the present invention, the urinary stone dissolving, coronary heart disease also takes a turn for the better, and whether illustrates that sclerosis coronarius and calcification softening awaiting have been taken place after taking medicine of the present invention confirmed.2, sildenafil citrate (viagra), curative effect was average when the scientist of Pfizer drugmaker found fundamental component nitric oxide (NO) the treatment cardiovascular diseases of viagra, but can bring the improvement of male erection function, because nitric oxide can distend the blood vessels, the neonate that is used for the treatment of apoplexy, agenesis of lung is significant, and goes on the market in the U.S. in 1998.3, laughing gas, i.e. nitrous oxide, though few in human body, also can in synthetic, obtain by arginic amino acid synthetase.As the transmitter substance between nerve and the cell, in each system of human body, serve as the key player.
Contain the water of crystallization aluminum potassium sulfate.Molecular formula: KAl (SO
4)
212H
2O; Formula weight: 474.39; Form: colourless cube, density: 1.7579/cm
3Fusing point: 92.5 ℃; In the time of 64.5 ℃, lose 9 molecular crystalline water; Lose the water of crystallization of 12 molecules in the time of 200 ℃; Dissolubility: be easy to water-solublely, form gluey aluminium hydroxide, i.e. Al (OH)
3Be insoluble to ethanol, the aluminium hydroxide absorption affinity of jelly is very strong, can make through the potassium per nitrate oxidation, loosening calculus surfaces material to break away from the calculus parent, discharges with urine.Oral suction volume is excessive, influences the absorption of calcium ferrum.The aluminum potassium sulfate that contains water of crystallization precipitates immediately at the external serum that can make, and showing has powerful coagulated protein effect (save during poisoning, answer oral milk, Ovum Gallus domesticus album etc.).In medicine, aluminium hydroxide is used for and gastric acid.
The specific embodiment
Instructions of taking: under the general state, take the 6-10 capsules every day, about 5-10 gram, severe renal hydrops can be obeyed about 15.Use low dose in hydrops instead after discharging.Taking medicine after meal, clothes several times as far as possible, each 2-3 grain is for well.While polydipsia water.Be used to prevent urinary calculi after the healing, but obey a capsules every day,, can prevent in advance for the crowd of district occurred frequently age bracket occurred frequently.
Carcinogenecity of the present invention, teratogenecity it be unclear that, and also effective in cure to urate calculus, mechanism it be unclear that.
The present invention has eliminated lithotrite and surgical calculus removing basically, in the over thousands of routine uriasis people who has treated, and none failure.
Claims (1)
1, a kind of preparation of dissolving the chemical drugs of urinary calculi.It is characterized in that: mix the back porphyrize with the aluminum potassium sulfate that contains water of crystallization by potassium nitrate and re-use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100465018A CN101401817A (en) | 2008-11-07 | 2008-11-07 | Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100465018A CN101401817A (en) | 2008-11-07 | 2008-11-07 | Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101401817A true CN101401817A (en) | 2009-04-08 |
Family
ID=40536066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100465018A Pending CN101401817A (en) | 2008-11-07 | 2008-11-07 | Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101401817A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288857A (en) * | 2018-10-09 | 2019-02-01 | 南方医科大学 | Application of the potassium nitrate in the drug that preparation prevents and treats calculus |
-
2008
- 2008-11-07 CN CNA2008100465018A patent/CN101401817A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288857A (en) * | 2018-10-09 | 2019-02-01 | 南方医科大学 | Application of the potassium nitrate in the drug that preparation prevents and treats calculus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Johnson et al. | Acute barium poisoning with respiratory failure and rhabdomyolysis | |
| CN106616177A (en) | Composite polypeptide solid beverage with curative effect of decreasing uric acid, and preparation method of composite polypeptide solid beverage | |
| CN101401817A (en) | Preparation for pharmaceutical chemicals for solubilizing uropoiesis stone | |
| WO2013139274A1 (en) | Sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration | |
| Chowdhury et al. | Puffer fish (Tetrodotoxin) poisoning: an analysis and outcome of six cases | |
| Barešic et al. | Survival after severe acute chromic acid poisoning complicated with renal and liver failure | |
| Underhill | Toxicology; Or, The Effects of Poisons | |
| Challoner et al. | Ammonium nitrate cold pack ingestion | |
| Arena | Poisoning—General Treatment and Prevention: Part II | |
| Eknoyan | A history of diuretics | |
| JP2948122B2 (en) | Pharmaceutical for enhancing muscle protein formation and muscle substance metabolism and method for producing the pharmaceutical | |
| CN107281192A (en) | A kind of composition for mitigating, treating and prevent rheumatoid arthritis | |
| JP2579593B2 (en) | Health food containing calcium-containing composition excellent in absorbability, drug containing the composition | |
| Yadav | Pharmacology & Toxicology | |
| Korinek | Veterinary medicines, their actions, uses and dose | |
| RU2217138C1 (en) | Composite "vitalizin-2" for prophylaxis of atherosclerosis, cardiovascular diseases and maintaining therapy in viral diseases | |
| RU2274457C1 (en) | Method for applying chronotherapy to oxalate nephropathy patients | |
| EP3071233B1 (en) | COMPOSITIONS FOR OBTAINING AN IMPROVED LUNG FUNCTION COMPRISING ACTIVATED CARBON COMPRISING ADSORBED IODINE AND/OR AN ADSORBED IODIDE SALT AND& xA;A SODIUM/IODIDE SYMPORTER INHIBITOR. | |
| Mutch | Drugs in the treatment of rheumatic disorders | |
| Tofield et al. | Hands-on guide to clinical pharmacology | |
| CN109432410A (en) | Application of the ferroheme in the drug of prevention and/or improvement altitude sickness, Food and hygienical food | |
| RU2217141C1 (en) | Composite "vitalizin-1" for prophylaxis of atherosclerosis, cardiovascular diseases and maintaining therapy in viral diseases | |
| AU2002312652B2 (en) | Laxative preparation | |
| CN107823268A (en) | A kind of anti-inflammatory for treating rhinitis is dusted agent | |
| TRAUT et al. | HYPERGUANIDEMIA IN TETANY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090408 |